Donafenib for Previously Treated Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The investigators do the clinical trial (patients with metastatic colorectal cancer treated
with donafenib/placebo after failure of standard therapy) to assess efficacy and safety of
donafenib in patients with metastatic colorectal cancer, progressing after all approved
standard therapies.